8-K current report · filed Aug 10, 2026

DiaMedica Therapeutics Inc. (DMAC) 8-K Current Report: August 10, 2026

Item 2.02Item EX-99.1DMAC overview

Short answer

DiaMedica Therapeutics Inc. (DMAC) filed an 8-K current report with the SEC on August 10, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 financial results announced for quarter ended June 30, 2026.

DiaMedica Therapeutics Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q2 2026 financial results announced for quarter ended June 30, 2026
  • Full condensed financial results available in Exhibit 99.1, relevant for assessing liquidity and operating performance

Item EX-99.1 · Exhibit EX-99.1

  • Q2 net loss $10.1M, up from $7.7M, with R&D expense rising to $8.2M from $5.8M
  • Cash, equivalents and investments $43.5M, down from $59.9M at December 31, 2025, supporting planned operations through 2027
  • DM199 reduced systolic blood pressure 29.1 mmHg and diastolic pressure 17.0 mmHg in 15 late-onset preeclampsia patients, both p<0.001
  • Early-onset fetal growth restriction cohort enrolled 6 participants at 5 µg/kg, with topline results expected in September
  • ReMEDy2 stroke trial surpassed 85% enrollment toward 200 participants, with interim analysis anticipated in early 2027

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other DiaMedica Therapeutics Inc. 8-K filings

Get the next DMAC 8-K as it lands

Follow DMAC for push alerts, or ask the research agent what this filing means.